Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study

doi:10.4251/wjgo.v15.i4.689

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4078)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

144

WORD

HTML

1724

Figures (1-5)

285

Tables (1-3)

239

Sum=2434

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

241

Download

602

Sum=843

Publishing Process of This Article

Item

Count

Browse

199

Download

602

Sum=801

Apr 15, 2023 (publication date) through Feb 14, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Apr 15, 2023; 15(4): 689-699
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689

Full Size Figure Download Figure

Figure 4 Spider plot displaying tumor response in 25 patients with hypothyroidism. PD: Progressive disease; SD: Stable disease; PR: Partial response; TBS: Tumor burden score.

Citation: Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699
URL: https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i4.689